Clinical Trials Logo

Filter by:
NCT ID: NCT05942560 Not yet recruiting - Depression Clinical Trials

Effects of CBT-Based Intervention Among Patients With Liver Cancer

Start date: December 30, 2023
Phase: N/A
Study type: Interventional

This study investigates the effects of a CBT- based intervention on depression, anxiety, immune function, quality of life, and overall survival. It also explores if the effects of the intervention on immune function and quality of life are mediated through the improvements in depression and anxiety among patients with liver cancer.

NCT ID: NCT05942378 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors

Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study evaluating the efficacy and safety of HRXG-K-1939 in combination with Adebrelimab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in patients with advanced solid tumors. HRXG-K-1939 will be administered to patients in a dose escalation regimen to determine a recommended dose for expansion.

NCT ID: NCT05940987 Not yet recruiting - Clinical trials for Pancreatitis, Chronic

Phone-based Smoking Cessation Intervention for Patients With Chronic Pancreatitis.(START)

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This study aims to explore whether regular telephone intervention in patients with chronic pancreatitis can improve their smoking cessation rate.

NCT ID: NCT05940428 Not yet recruiting - Clinical trials for Diabetic Macular Edema

A Study of ASKG712 in Patients With Diabetic Macular Edema

Start date: July 30, 2023
Phase: Phase 1
Study type: Interventional

This multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion study will investigate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 following intravitreal administration in patients with diabetic macular edema (DME).

NCT ID: NCT05940116 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Start date: July 20, 2023
Phase: Phase 1
Study type: Interventional

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.

NCT ID: NCT05939154 Not yet recruiting - Mental Disorder Clinical Trials

Early Identification of Mental Disorders: Application of a Multi-modal & Domains System

Start date: August 1, 2023
Phase:
Study type: Observational

This study aims to build a multi-modal collection template and establish a multi-modal database of seven mental disorders including depressive disorders, bipolar disorders, schizophrenia, obsessive-compulsive disorder, anxiety disorders, addictive disorders and sleep-wake disorders by collecting voice information, facial micro-expression, eye tracking, EEG physiology data respectively. This study will contribute to the multi-modal diagnosis of major mental disorders such as depression in the future and realize clinical application.

NCT ID: NCT05936281 Not yet recruiting - Acute Gout Clinical Trials

Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy

Gensci 048-202
Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Genakumab for Injection in patients with gout initiating urico-lowering therapy

NCT ID: NCT05933668 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor

Start date: July 2023
Phase: Phase 1
Study type: Interventional

This study is a single center, open, single arm, dose increasing early clinical study. The purpose of this study is to evaluate the safety and efficacy of YK0901 immunotherapy in the treatment of patients with advanced solid tumor whose tumor antigen KRAS G12V expression is positive (HLA-A * 11:01).

NCT ID: NCT05932264 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Start date: July 2023
Phase: Phase 2
Study type: Interventional

This is a phase 2, open-label study to evaluate the efficacy and safety of combination of Apatinib and Fluzoparib with or without Adebrelimab in previously-treated TP53-mutant advanced non-small cell lung cancer.

NCT ID: NCT05932212 Not yet recruiting - Vulvar Cancer Clinical Trials

A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer

Start date: August 15, 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104, an anti- PD-1 and CTLA-4 bispecific antibody, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.